Echinocandins in children

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages 508-509

  Hoffman, Jill A ^a   Walsh, Thomas J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

antifungal; aspergillus; candida; echinocandins

Indexed keywords

AMINOCANDIN; AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL ABSCESS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDA ENDOCARDITIS; CANDIDEMIA; CANDIDIASIS; CHILD; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MENINGOENCEPHALITIS; NEPHROTOXICITY; PERITONITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; VOMITING;

EID: 79957975048     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31821b95e2     Document Type: Review

References (19)

1. Pfaller MA, et al. Correlation of MIC with outcome for Candida species. J Clin Microbiol. 2008;46:2620-2629.
2. Garcia-Effron G, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis. Antimicrob Agents Chemother. 2008;52:2305-2312.
3. Andes D, et al. In vivo comparison of the pharmacodynamic targets. Antimicrob Agents Chemother. 2010;54:2497-2506.
4. Hohl TM, et al. Caspofungin modulates inflammatory responses to Aspergillus fumigatus. J Infect Dis. 2008;198:176-185.
5. Wiederhold NP, et al. Paradoxical echinocandin activity. Med Mycol. 2009;47:5369-5375.
6. Fortwendel JR, et al. Transcriptional regulation of chitin synthase. Antimicrob Agents Chemother. 2010;54:1555-1563.
7. Benjamin DK, et al. Safety and pharmacokinetics of intravenous anidulafungin in children. Antimicrob Agents Chemother. 2006;50:632-638.
8. Walsh TJ, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49: 4536-4545. (Pubitemid 41552583)
9. Maertens JA, et al. A randomized, double blind, multicenter study of caspofungin versus liposomal amphotericin b. Pediatr Infect Dis J. 2010; 29:415-420.
10. Walsh TJ, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med. 2004;351:1391-1402.
11. Zaoutis TE, et al. A prospective, multicenter study of caspofungin for the treatment. Pediatrics. 2009;123:877-884.
12. Odio CM, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23:1093-1097. (Pubitemid 40812754)
13. Seibel NL, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463). Antimicrob Agents Chemother. 2005;49:3317-3324.
14. Van Burik JH, et al. Micafungin versus fluconazole for prophylaxis. Clin Infect Dis. 2004;39: 1407-1416.
15. Hope WW, et al. Population pharmacokinetics of micafungin. Antimicrob Agents Chemother. 2010; 54:2633-2637.
16. Smith PB, et al. Pharmacokinetics of an elevated dosage of micafungin. Pediatric Infect Dis J. 2009;28:412-415.
17. Hope WW, et al. The pharmacokinetics and pharmacodynamics of micafungin. J Infect Dis. 2008; 197:163-171.
18. Queiros-Telles F, et al. Micafungin versus liposomal amphotericin B for pediatric. Pediatr Infect Dis J. 2008;27:820-826.
19. Sandage B, et al. Pharmacokinetics and fungicidal activity of aminocandin. In: 15th European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark; 2005. Abstract P-1115.